STOCK TITAN
  1. Home
  2. News
  3. TEVA

Teva Pharm (TEVA) Stock News

TEVA NYSE

Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.

Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.

As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.

News

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Rhea-AI Summary
Teva Pharmaceuticals revealed concerning findings about tardive dyskinesia (TD) treatment in long-term care facilities. The study showed that over 50% of LTC residents with TD don't receive standard care treatment, and 25% receive no treatment at all. Among residents on antipsychotic drugs, 5.6% were diagnosed with extrapyramidal syndrome while only 1.1% received specific TD diagnosis. The research, analyzing ~700,000 residents on antipsychotic drugs and ~35,000 on Reglan, found mood disorders as the most common underlying condition (68% and 54% respectively). Common comorbidities included dementia, chronic pulmonary disease, and congestive heart failure. Less than half of TD patients received the recommended VMAT2 inhibitor treatment, with most receiving non-FDA approved treatments like benztropine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Rhea-AI Summary
Teva Pharmaceuticals presented significant data for its schizophrenia treatment portfolio at the 2025 Psych Congress Elevate Annual Meeting. Real-world studies of UZEDY (risperidone) showed superior outcomes compared to oral treatments, including lower relapse rates (9.0% vs 15.4-16.8%), better adherence (71.3% vs 52.8%), and reduced healthcare costs ($18,796 vs $26,376). UZEDY patients also experienced fewer hospital visits and shorter stays. Additionally, Teva's investigational drug TEV-'749 (olanzapine) demonstrated promising Phase 3 SOLARIS trial results, with no post-injection delirium/sedation syndrome (PDSS) reported after 3,400+ injections, while meeting primary efficacy endpoints across all dosing groups with significant PANSS score improvements versus placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
clinical trial
-
News

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) unveiled its acceleration phase of "Pivot to Growth" strategy at its 2025 Innovation & Strategy Day. The company has achieved 9 consecutive quarters of growth and generated over $2.3 billion in revenue in 2024 from its innovative portfolio. Teva aims to build a $5+ billion innovative medicines franchise by 2030, led by AUSTEDO®, AJOVY®, and UZEDY®. Key targets include AUSTEDO sales exceeding $3 billion by 2030 and LAI schizophrenia franchise reaching $1.5-2.0 billion in peak sales. The company's late-stage pipeline includes promising assets like duvakitug (potential $2-5B peak sales) and DARI (~$1B potential). Teva reaffirmed its 2027 financial targets, including 30% operating margin, $2.7+ billion free cash flow, and plans for $700 million in net savings through organizational modernization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
News

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) has received Fast Track designation from the FDA for TEV-53408, an anti-IL-15 antibody being developed for celiac disease treatment. The drug candidate is currently in Phase 2a trials evaluating its efficacy and safety in adult celiac patients on a gluten-free diet. TEV-53408 works by inhibiting interleukin-15 (IL-15) to prevent intestinal damage and associated symptoms. The Fast Track status highlights the treatment's potential and the significant unmet medical need in celiac disease, which affects approximately 1% of the global population. This development demonstrates Teva's commitment to expanding its innovative pipeline in immunological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
clinical trial fda approval
-
News

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced upcoming presentations by its executive management team at two major healthcare conferences in June 2025. At the Jefferies Global Healthcare Conference on June 4, EVP U.S. Commercial Chris Fox and EVP Global R&D and Chief Medical Officer Dr. Eric Hughes will present at 9:20 am ET. At the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, President & CEO Richard Francis will present at 8:00 am ET. Live webcasts will be available on Teva's Investor Relations website, with archived versions accessible within 24 hours after each presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
conferences
-
News

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Rhea-AI Summary
Teva Pharmaceutical and Biolojic Design have initiated IND-enabling studies for BD9, a novel dual-specific multibody targeting both TSLP and IL-13 for treating atopic dermatitis and asthma. BD9 was developed using Biolojic's Multibody Platform, which creates antibodies capable of addressing multiple disease targets simultaneously. The therapy aims to improve outcomes for patients with TH2-driven inflammatory diseases where current treatments are inadequate. This development aligns with Teva's Pivot to Growth strategy to enhance innovation in their pipeline. Under the agreement, Teva holds worldwide development rights for BD9, while Biolojic is eligible for milestone payments based on pre-clinical, clinical, regulatory, and commercial achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
none
News

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) has announced an increase in its debt tender offer from $2.0 billion to $2.25 billion. The company is also raising the Pool Tender Caps for Pool 2 Notes and Pool 3 Notes from $250 million to $350 million each. This follows Teva's successful pricing of approximately $2.3 billion in senior notes on May 20, 2025. The tender offer includes multiple series of notes with varying interest rates and maturities, structured in three pools. Pool 1 has a maximum amount of $1.55 billion, while Pool 2 and Pool 3 each have a cap of $350 million. The offer expires on June 17, 2025, with an Early Tender Time of June 2, 2025. Holders who tender by the Early Tender Time will receive the Total Consideration, which includes an Early Tender Premium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
-
News

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Rhea-AI Summary
Teva Pharmaceutical has successfully upsized and priced approximately $2.3 billion in senior notes, increased from the previously announced $2 billion. The notes consist of: €1 billion of 4.125% EUR-denominated notes maturing in 2031, $500 million of 6.000% USD-denominated notes maturing in 2032, and $700 million of 5.750% USD-denominated notes maturing in 2030. The proceeds will be used to fund tender offers for existing notes and repay outstanding debt. The settlement is expected around May 28, 2025. The notes will be unsecured senior obligations guaranteed by Teva and were offered through their shelf registration statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
News

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Rhea-AI Summary

Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Fitch Ratings Agency to BB+ from BB, with a stable outlook. The upgrade follows a recent rating improvement from Moody's and reflects Teva's successful debt reduction efforts and improved financial flexibility. Fitch's report highlights expected revenue growth from key products AUSTEDO and AJOVY, along with the company's promising biosimilar pipeline. The agency also noted that Teva's focus on optimizing external spend, resource allocation, and organizational modernization is anticipated to boost operating margins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
News

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) has launched tender offers to purchase up to $2 billion worth of senior notes due between 2026-2031. The tender offers cover six series of notes issued by Teva's finance subsidiaries and guaranteed by Teva, including both USD and EUR denominated securities. The offers are structured in three pools with specific caps: Pool 1 ($1.55B max), Pool 2 ($250M equivalent max), and Pool 3 ($200M equivalent max). Holders tendering by June 2, 2025 (Early Tender Time) will receive the Total Consideration including a $50/€50 premium per $1,000/€1,000 principal amount. The offers expire on June 17, 2025. Teva plans to fund these purchases through a new debt offering and cash on hand, aiming to proactively manage its debt structure and extend its maturity profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none

FAQ

What is the current stock price of Teva Pharm (TEVA)?

The current stock price of Teva Pharm (TEVA) is $34.29 as of May 15, 2026.

What is the market cap of Teva Pharm (TEVA)?

The market cap of Teva Pharm (TEVA) is approximately 41.1B.